Compare Twist Bioscience Corp (TWST) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twist Bioscience Corp vs Williams Companies Inc — how do they compare? Twist Bioscience Corp trades at $159.78 (market cap $10.08B), while Williams Companies Inc trades at $72.67 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 8.8× Twist Bioscience Corp's market cap, and Williams Companies Inc pays a 2.9% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Williams Companies Inc for 58 Days on average.
| TWST | WMB | |
|---|---|---|
Market Cap | $10.08B | $88.48B |
Volume | 4,229,037 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $205.00 | $79.40 |
52-Week Low | $25.45 | $56.51 |
Typical Hold Time | 27 Days | 58 Days |
Enterprise Value | $10.01B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twist Bioscience (TWST) trades at $152.05, down 2.31% today but remains near recent highs following a significant rally driven by AI partnerships and strong sector interest. The company shows improving revenue growth ($377M in 2025) but continues to post substantial losses (-$78M net income). Technical indicators show mixed signals with bullish overall sentiment but bearish moving averages, while analyst consensus remains positive with 73% buy ratings.
TWST presents a high-risk, high-reward opportunity with strong growth potential through AI-driven drug discovery partnerships but faces significant execution risks amid persistent profitability challenges. The stock's valuation appears stretched given current fundamentals, requiring successful commercialization of pipeline assets to justify premium multiples.
WMB trades at $72.34, up 1.23% with strong technical momentum and bullish analyst sentiment. The stock shows solid fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings beat expectations in Q1 2026, while technical indicators signal bullish momentum with support at $71-72 levels. The company benefits from natural gas demand growth driven by AI data center expansion and maintains stable fee-based revenue streams.
Outlook remains positive with 79% analyst buy ratings and $87.27 consensus target, representing 21% upside. Key opportunities include AI-driven natural gas demand and strategic acquisitions, while risks involve energy market volatility and high debt levels. The stock offers compelling value with strong cash flow generation and dividend growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
